CareDx: Specialist in Transplant Diagnostics Grows by 52% - Expansion into Oncology!
Reading Time: 3 minutes
CareDx focuses on testing services for patients after organ transplants. The acquisition of Naveris for up to $260 million marks the company's strategic entry into oncology. The second quarter impresses with a revenue increase of over 52%. A CMS decision could further boost demand through reimbursements. CareDx (CDNA) operates as a provider of precision medicine and primarily focuses on minimally invasive monitoring tests for patients after an organ transplant. By selling the laboratory products business to Eurobio Scientific for...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
